Bosentan

5 trials 1 recruiting CCardiology

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

1 Recruiting

2 Completed trials

5 Sponsors

14 Countries

Phase III

Phase II/III

Phase II

Phase III: 2 Phase II/III: 1 Phase II: 2

Oversight events:

1 serious breach across 1 trial

View oversight register →

Indications tested

Giant cell arteritis 1

Sponsors using this IMP

Actelion Pharmaceuticals Ltd. 1 Assistance Publique Hopitaux De Paris 1 Centre Hospitalier Universitaire Grenoble Alpes 1 Centre Hospitalier Universitaire Rouen 1 Stichting Radboud University Medical Center 1

All trials

5 total

VASCULAR AND RENAL IMPACT OF ENDOTHELIN-1 RECEPTOR BLOCKADE IN PATIENTS WITH UNCONTROLLED ARTERIAL HYPERTENSION - ENDOTHELIN-2 Pending

2024-515928-36-00 Phase II 1 country Centre Hospitalier Universitaire Rouen
Bosentan in the treatment of Giant Cell Arteritis Pending

2024-517030-17-00 Phase II 1 country Assistance Publique Hopitaux De Paris
Efficacy of endothelin receptor antagonism in treatment of coronary artery spasm: a randomized controlled clinical trial. (EDIT-CAS) Recruiting

2023-507782-25-00 Phase II/III 1 country Stichting Radboud University Medical Center
Parent and/or Legal Guardian ICF and Adult patient ICF: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study wi… Ended

2022-501012-34-00 Phase III 13 countries Actelion Pharmaceuticals Ltd.
Evaluation of the effects of bosentan in the management of patients in the acute phase of acute anterior ischemic optic neuropathy. Ended

2024-518345-21-00 Phase III 1 country Centre Hospitalier Universitaire Grenoble Alpes

Showing 1–5 of 5 trials

← All drugs A–Z